To further validate the P-Rex1 independence of Rac1 activation in prostate cancer cells, we examined the effect of the PI3K inhibitor BKM120 and gallein, an agent that disrupts Gβγ signaling. This evidence concerns the gene RAC1 and prostate cancer.